David Litwack

David Litwack has a diverse work experience in scientific strategy and communications in the pharmaceutical and research sectors. David began their career at the Salk Institute for Biological Studies as a Postdoctoral Researcher from June 1995 to January 2002. David then joined the University of Maryland School of Medicine as an Assistant Professor from January 2002 to July 2010.

In September 2010, Litwack became an AAAS Science & Technology Policy Fellow at the National Cancer Institute, serving until August 2012. David then joined the FDA as part of the Personalized Medicine Staff from September 2012 to March 2018. During their time at the FDA, they also worked in the Biomarker Qualification Program from March 2018 to August 2018.

Litwack's career continued to progress in the pharmaceutical industry, where they joined Prevail Therapeutics in September 2018 as the Director of Scientific Strategy and Communications. David held this position until June 2021 when they were promoted to Senior Director, and then again in October 2022 when they became the Associate VP of Scientific Strategy and Communications.

Additionally, Litwack has served as a Board Member for PRIM&R - Public Responsibility in Medicine and Research since January 2022.

Overall, Litwack's work experience showcases their expertise in scientific strategy, communications, and policy development in the pharmaceutical and research fields.

David Litwack completed their Bachelor of Science degree in Chemistry from the University of Chicago from 1984 to 1988. David then went on to pursue a Ph.D. in Biology at the Massachusetts Institute of Technology, where they studied from 1988 to 1995.